


# CDC-Funded HIV Testing in the United States, Puerto Rico and U.S. Virgin Islands

## 2018 ANNUAL HIV TESTING REPORT

### INTRODUCTION

The Centers for Disease Control and Prevention (CDC) receives, analyzes, and disseminates HIV test-level data reported by CDC-funded recipients through the National HIV Prevention Program Monitoring and Evaluation (NHM&E) data reporting system, EvaluationWeb®. These data are used to improve the impact of HIV testing efforts, inform programmatic activities, and document the progress of programs toward local, state, and national HIV prevention goals. NHM&E HIV test-level data are used in conjunction with other information (e.g., progress reports, surveillance data, and census data) by HIV program managers and policy makers, HIV testing service providers, CDC project officers, evaluators, researchers, and others interested in the public health implications of HIV prevention program activities. This report uses NHM&E HIV test-level data from 60 state and local health departments (HDs) and 100 community-based organizations directly funded by CDC through 5 funding opportunities (i.e., [PS15-1502](#), [PS15-1506](#), [PS15-1509](#), [PS17-1704](#), [PS18-1802](#)) to describe the demographics of persons tested, newly diagnosed with HIV, and linked to HIV medical care in the United States, Puerto Rico, and U.S. Virgin Islands in 2018.



### CDC-funded HIV testing by setting and site type

The tables below show the distribution of tests by site type in health care and non-health care settings. The majority of CDC-funded HIV tests were conducted in health care settings (73%). Additionally, 518 CDC-funded HIV tests were conducted in mobile units and 42,011 HIV tests were missing information on site type.

	TESTS (% NEW POSITIVITY)		TESTS (% NEW POSITIVITY)
<b>Health care setting</b>	<b>2,002,219 (0.3%)</b>	<b>Non-health care setting</b>	<b>713,464 (0.6%)</b>
Emergency Department	352,809 (0.2%)	HIV Testing Site	335,184 (0.8%)
STD Clinics	621,673 (0.4%)	Community Settings <sup>c</sup>	216,611 (0.5%)
Community Health Centers	469,784 (0.3%)	Correctional Facilities, Non-health care	46,189 (0.2%)
Correctional Clinics	134,180 (0.2%)	Other <sup>d</sup>	115,480 (0.3%)
Other <sup>b</sup>	423,773 (0.3%)		

<sup>a</sup> Reported percentage excludes tests with missing/invalid outcome data. Timeframe for linkage to HIV medical care calculated at 90 days to include data from all 5 funding opportunities.

<sup>b</sup> Health care sites other than those specified where medical services are provided including primary care clinics, substance abuse treatment facilities, pharmacies, dental clinics, TB clinics, and inpatient hospitals.


<sup>c</sup> Includes school/education facility, church/mosque/synagogue/temple, shelter/transitional housing, commercial facility, bar/club/adult entertainment, public area, individual residence, and other community settings.

<sup>d</sup> Non-health care sites other than those specified including health department field visits and syringe exchange programs.


## Newly diagnosed HIV positivity by age, gender, race/ethnicity and subpopulation

A total of 2,758,212 CDC-funded HIV tests were conducted and 10,622 (0.4%) persons were newly diagnosed with HIV. The figures below show the percentage of CDC-funded tests conducted that identified persons newly diagnosed with HIV by demographic and subpopulation categories. Additional information, including number of tests conducted by category, can be found in Appendix Table 4.


### AGE <sup>a</sup>




### GENDER <sup>b</sup>



### RACE & ETHNICITY <sup>c</sup>



### SUBPOPULATION in Non-health Care Settings <sup>d</sup>



<sup>a</sup> "<13 years" category is not shown.

<sup>b</sup> Transgender is defined as a person whose current gender identity differs from their sex assigned at birth. "Other gender" category is not shown.

<sup>c</sup> "Multi-race" category is not shown.

<sup>d</sup> Restricted to non-health care settings because data on subpopulation are required for all CDC-funded tests performed in non-health care settings, but only required for HIV-positive tests in health care settings. "MSM/IDU" includes males who reported both male-to-male sexual contact and injection drug use in the past 12 months. "MSM" includes males who reported male-to-male sexual contact in the past 12 months. "Persons who inject drugs (PWID)" includes persons who reported injection drug use in the past 12 months. Subpopulation categories not shown include: "women who have sex with women," "transgender," and "transgender/IDU."

## CDC-funded HIV testing and linkage to HIV medical care

Among persons newly diagnosed with HIV, 86% were linked to HIV medical care within 90 days\* of their positive test. The reported linkage percentage varied by jurisdiction, as shown in Table 1 below.

**Table 1. CDC-funded HIV testing and linkage to HIV medical care within 90 days among persons newly diagnosed with HIV in the United States, Puerto Rico and U.S. Virgin Islands, 2018**

Jurisdictions	CDC-funded HIV tests		
	Number of HIV tests conducted in 2018	Number (%) of persons newly diagnosed with HIV	Percentage of persons newly diagnosed with HIV linked to HIV medical care within 90 days*
Alabama	88,628	129 (0.1%)	48%
Alaska	1,796	2 (0.1%)	100%
Arizona <sup>a</sup>	38,713	257 (0.7%)	79%
Arkansas <sup>a</sup>	37,709	136 (0.4%)	24%
California			
Los Angeles <sup>a</sup>	101,591	666 (0.7%)	85%
San Francisco	33,567	111 (0.3%)	90%
California <sup>a</sup> (excludes Los Angeles and San Francisco)	54,595	308 (0.6%)	78%
Colorado <sup>b</sup>	2,118	16 (0.8%)	75%
Connecticut <sup>d</sup>	62,122	112 (0.2%)	91%
Delaware <sup>d</sup>	10,565	16 (0.2%)	70%
District of Columbia <sup>b d</sup>	19,524	78 (0.4%)	98%
Florida	341,836	1,635 (0.5%)	98%
Georgia <sup>d</sup>	136,201	1,041 (0.8%)	81%
Hawaii	3,131	19 (0.6%)	71%
Idaho <sup>d</sup>	4,103	5 (0.1%)	100%
Illinois			
Chicago <sup>a b</sup>	66,205	117 (0.2%)	60%
Illinois <sup>b</sup> (excludes Chicago)	28,778	48 (0.2%)	75%
Indiana <sup>d</sup>	19,944	77 (0.4%)	81%
Iowa	10,657	26 (0.2%)	100%
Kansas	16,951	62 (0.4%)	93%
Kentucky <sup>d</sup>	20,474	75 (0.4%)	95%
Louisiana	111,978	458 (0.4%)	83%
Maine	1,610	4 (0.2%)	75%
Maryland			
Baltimore <sup>d</sup>	45,350	143 (0.3%)	71%
Maryland <sup>d</sup> (excludes Baltimore)	35,391	99 (0.3%)	73%
Massachusetts <sup>a d</sup>	39,735	159 (0.4%)	94%
Michigan <sup>b d</sup>	52,484	137 (0.3%)	95%
Minnesota <sup>b d</sup>	4,963	13 (0.3%)	100%
Mississippi <sup>c d</sup>	54,182	124 (0.2%)	88%
Missouri <sup>a b</sup>	91,179	225 (0.2%)	88%
Montana <sup>d</sup>	2,075	1 (0.1%)	100%
Nebraska <sup>d</sup>	8,644	19 (0.2%)	50%
Nevada	21,205	171 (0.8%)	88%
New Hampshire <sup>d</sup>	895	7 (0.8%)	18%
New Jersey <sup>d</sup>	27,993	181 (0.6%)	100%
New Mexico	7,509	24 (0.3%)	92%
New York			
New York City <sup>b</sup>	84,332	441 (0.5%)	84%
New York <sup>b</sup> (excludes New York City)	26,553	237 (0.9%)	98%

## CDC-funded HIV testing and linkage to HIV medical care (continued)

**Table 1. CDC-funded HIV testing and linkage to HIV medical care within 90 days among persons newly diagnosed with HIV in the United States, Puerto Rico and U.S. Virgin Islands, 2018 (continued)**

Jurisdictions	CDC-funded HIV tests		
	Number of HIV tests conducted in 2018	Number (%) of persons newly diagnosed with HIV	Percentage of persons newly diagnosed with HIV linked to HIV medical care within 90 days*
North Carolina <sup>d</sup>	169,769	310 (0.2%)	94%
North Dakota <sup>d</sup>	4,958	11 (0.2%)	90%
Ohio	51,887	269 (0.5%)	93%
Oklahoma <sup>a b</sup>	10,680	47 (0.4%)	88%
Oregon	7,197	36 (0.5%)	86%
Pennsylvania			
Pennsylvania (excludes Philadelphia)	60,196	122 (0.2%)	92%
Philadelphia <sup>b</sup>	51,463	181 (0.4%)	89%
Rhode Island <sup>d</sup>	3,089	6 (0.2%)	100%
South Carolina <sup>d</sup>	62,180	265 (0.4%)	95%
South Dakota <sup>d</sup>	1,764	3 (0.2%)	0%
Tennessee <sup>d</sup>	116,042	444 (0.4%)	83%
Texas			
Houston	107,133	300 (0.3%)	96%
Texas <sup>d</sup> (excludes Houston)	274,551	738 (0.3%)	70%
Utah <sup>b d</sup>	2,568	15 (0.6%)	89%
Vermont	424	3 (0.7%)	100%
Virginia <sup>d</sup>	63,074	218 (0.3%)	91%
Washington <sup>d</sup>	14,190	63 (0.4%)	95%
West Virginia	5,106	9 (0.2%)	100%
Wisconsin	14,957	46 (0.3%)	100%
Wyoming	3,977	4 (0.1%)	100%
Puerto Rico	16,205	137 (0.8%)	97%
U.S. Virgin Islands <sup>d</sup>	1,516	16 (1.1%)	87%
<b>Total</b>	<b>2,758,212</b>	<b>10,622 (0.4%)</b>	<b>86%</b>

\*Reported percentage of persons newly diagnosed with HIV linked to HIV medical care within 90 days excludes tests with missing/invalid outcome data. Timeframe for linkage calculated at 90 days to include data from all 5 funding opportunities.

<sup>a</sup> Recipients cited reporting delays resulting in artificially fewer tests under PS18-1802.

<sup>b</sup> Recipients reported shifts in funding allocation impacting total number of CDC-funded tests under PS18-1802.

<sup>c</sup> Recipients reported other programmatic issues impacting data reported (e.g., staff reduction, suspension of screening at large clinical facilities).

<sup>d</sup> Recipients reported data under both the old and the new NHM&E reporting requirements in 2018.

# CDC-Funded HIV Testing in the United States, Puerto Rico and U.S. Virgin Islands

## 2018 ANNUAL HIV TESTING REPORT

### TECHNICAL NOTES

Data presented in this report include CDC-funded HIV tests conducted in 2018 and reported to CDC as of September 16, 2019 by 60 state and local health departments and 100 community-based organizations in the United States, Puerto Rico, and the U.S. Virgin Islands. An HIV test is a sequence of one or more HIV tests conducted to determine a person's HIV status. Total tests include only tests with negative or positive results; tests with discordant or inconclusive results are excluded. A person with newly diagnosed HIV is a person who tests positive on the current test and has no indication of a previous positive test (includes persons with unconfirmed preliminary positive rapid tests and persons with confirmed positive tests). The reported percentage of persons linked to HIV medical care within 90 days is calculated by excluding tests with missing/invalid outcome data from the denominator, which likely overestimates actual performance.

### INTERPRETING THIS REPORT

When interpreting data in this report, several points should be considered.

- Data included in the 2018 Annual HIV Testing Report were collected while jurisdictions transitioned to new NHM&E data reporting requirements. Therefore, this report does not fully reflect all CDC-funded HIV testing and programmatic activities conducted in 2018 and cannot be directly compared to previous CDC-funded Annual HIV Testing Reports (i.e., 2018 data cannot be used for trend analysis). For the 28 HDs that reported under both the old and the new reporting requirements in 2018, data were analyzed separately and resulting counts were combined in the tables and figures displayed.
- Data included in this report represent test records rather than individuals. Clients tested multiple times may be included in the dataset.
- Procedures for data collection and verification vary among jurisdictions. For example, some jurisdictions accept a client's self-report as adequate evidence that the client is newly diagnosed or has been linked to HIV medical care; whereas others require a cross-check with the surveillance system to rule out prior diagnosis or to verify linkage to care.
- Jurisdictions vary considerably in resources available for HIV prevention and in the contexts in which they operate, which can affect program capacity. For example, some jurisdictions may receive state and local funds in addition to federal funds, whereas others may not. Examples of contextual issues that may affect program performance include HIV prevalence, geography, political environment, laws and regulations, program infrastructure, surveillance system capacity, and accessibility to surveillance data to help guide program activities.
- The population accessing HIV testing services at publicly funded sites is not necessarily representative of all persons who are tested in the United States; therefore, these findings should not be applied to the general United States population. Reliable estimates are not available to determine what proportion of all HIV tests in the United States are CDC-funded.

### ACKNOWLEDGEMENTS

This report was prepared by Nicoline Collins, Guoshen Wang, Carolyn Wright, Tanesha Joshua, Hui Zhao, Amanda Ray, Gary Uhl, and Shubha Rao of the Program Evaluation Branch in the Division of HIV/AIDS Prevention. Publication of this report would not have been possible without the hard work and dedication of state and local health departments and community-based organizations that collected and submitted the HIV test-level data. We also acknowledge the contributions of Janet Heitgerd and Lisa Belcher of the Program Evaluation Branch; the Quantitative Sciences and Data Management Branch; and the Prevention Program Branch for their contribution toward monitoring and strengthening HIV prevention efforts in state and local health departments and community-based organizations.

Suggested citation: Centers for Disease Control and Prevention. *CDC-Funded HIV Testing in the United States, Puerto Rico, and the U.S. Virgin Islands, 2018*. <http://www.cdc.gov/hiv/library/reports/index.html>. Published August 2020. Accessed [Date].

# CDC-Funded HIV Testing in the United States, Puerto Rico and U.S. Virgin Islands

## 2018 ANNUAL HIV TESTING REPORT

### APPENDIX: DETAILED TABLES

**Table 1.** Number of CDC-funded HIV tests and HIV positivity, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2018

**Table 2.** Number of CDC-funded HIV tests and newly diagnosed HIV positivity in health care and non-health care settings, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2018

**Table 3.** CDC-funded HIV testing and linkage to HIV medical care among persons newly diagnosed with HIV, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2018

**Table 4.** CDC-funded HIV testing and linkage to HIV medical care among persons newly diagnosed with HIV by demographic characteristics, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2018

#### **For more information, contact:**

Division of HIV/AIDS Prevention  
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention  
U.S. Centers for Disease Control and Prevention  
1600 Clifton Road NE, MS E-59, Atlanta, GA 30333  
Phone: 1-800-CDC-INFO  
Web address: <http://www.cdc.gov/HIV>

National HIV Prevention Program Monitoring and Evaluation Service Center Phone: 1-855-374-7310,  
Email: [NHMEservice@cdc.gov](mailto:NHMEservice@cdc.gov)

**Table 1. Number of CDC-funded HIV tests and HIV positivity, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2018**

CDC-funded jurisdiction	HIV tests <sup>a</sup>	HIV-positive tests <sup>b</sup>							
		Newly diagnosed HIV-positive tests <sup>c</sup>		Previously diagnosed HIV-positive tests <sup>d</sup>		Unable to determine prior HIV status <sup>e</sup>		Total	
		No.	(%)	No.	(%)	No.	(%)	No.	(%)
Alabama	88,628	129	(0.1)	334	(0.4)	165	(0.2)	628	(0.7)
Alaska	1,796	2	(0.1)	1	(0.1)	0	(0.0)	3	(0.2)
Arizona	38,713	257	(0.7)	71	(0.2)	53	(0.1)	381	(1.0)
Arkansas	37,709	136	(0.4)	111	(0.3)	12	(0.0)	259	(0.7)
California									
Los Angeles	101,591	666	(0.7)	395	(0.4)	35	(0.0)	1,096	(1.1)
San Francisco	33,567	111	(0.3)	400	(1.2)	0	(0.0)	511	(1.5)
California (excludes Los Angeles and San Francisco)	54,595	308	(0.6)	192	(0.4)	35	(0.1)	535	(1.0)
Colorado	2,118	16	(0.8)	21	(1.0)	0	(0.0)	37	(1.7)
Connecticut <sup>f</sup>	62,122	112	(0.2)	23	(0.0)	6	(0.0)	141	(0.2)
Delaware <sup>f</sup>	10,565	16	(0.2)	8	(0.1)	9	(0.1)	33	(0.3)
District of Columbia <sup>f</sup>	19,524	78	(0.4)	55	(0.3)	76	(0.4)	209	(1.1)
Florida	341,836	1,635	(0.5)	1,968	(0.6)	0	(0.0)	3,603	(1.1)
Georgia <sup>f</sup>	136,201	1,041	(0.8)	615	(0.5)	32	(0.0)	1,688	(1.2)
Hawaii	3,131	19	(0.6)	5	(0.2)	0	(0.0)	24	(0.8)
Idaho <sup>f</sup>	4,103	5	(0.1)	5	(0.1)	0	(0.0)	10	(0.2)
Illinois									
Chicago	66,205	117	(0.2)	280	(0.4)	11	(0.0)	408	(0.6)
Illinois (excludes Chicago)	28,778	48	(0.2)	35	(0.1)	2	(0.0)	85	(0.3)
Indiana <sup>f</sup>	19,944	77	(0.4)	23	(0.1)	24	(0.1)	124	(0.6)
Iowa	10,657	26	(0.2)	8	(0.1)	0	(0.0)	34	(0.3)
Kansas	16,951	62	(0.4)	10	(0.1)	0	(0.0)	72	(0.4)
Kentucky <sup>f</sup>	20,474	75	(0.4)	55	(0.3)	28	(0.1)	158	(0.8)
Louisiana	111,978	458	(0.4)	837	(0.7)	1	(0.0)	1,296	(1.2)
Maine	1,610	4	(0.2)	4	(0.2)	0	(0.0)	8	(0.5)
Maryland									
Baltimore <sup>f</sup>	45,350	143	(0.3)	400	(0.9)	20	(0.0)	563	(1.2)
Maryland (excludes Baltimore)	35,391	99	(0.3)	117	(0.3)	0	(0.0)	216	(0.6)
Massachusetts <sup>f</sup>	39,735	159	(0.4)	491	(1.2)	0	(0.0)	650	(1.6)
Michigan <sup>f</sup>	52,484	137	(0.3)	125	(0.2)	16	(0.0)	278	(0.5)
Minnesota <sup>f</sup>	4,963	13	(0.3)	10	(0.2)	0	(0.0)	23	(0.5)
Mississippi <sup>f</sup>	54,182	124	(0.2)	348	(0.6)	13	(0.0)	485	(0.9)
Missouri	91,179	225	(0.2)	288	(0.3)	14	(0.0)	527	(0.6)
Montana <sup>f</sup>	2,075	1	(0.0)	1	(0.0)	1	(0.0)	3	(0.1)
Nebraska <sup>f</sup>	8,644	19	(0.2)	11	(0.1)	5	(0.1)	35	(0.4)
Nevada	21,205	171	(0.8)	77	(0.4)	0	(0.0)	248	(1.2)
New Hampshire <sup>f</sup>	895	7	(0.8)	1	(0.1)	0	(0.0)	8	(0.9)

CDC-funded jurisdiction	HIV-positive tests <sup>b</sup>								
	HIV tests <sup>a</sup>	Newly diagnosed HIV-positive tests <sup>c</sup>		Previously diagnosed HIV-positive tests <sup>d</sup>		Unable to determine prior HIV status <sup>e</sup>		Total	
	No.	No.	(%)	No.	(%)	No.	(%)	No.	(%)
New Jersey <sup>f</sup>	27,993	181	(0.6)	169	(0.6)	3	(0.0)	353	(1.3)
New Mexico	7,509	24	(0.3)	10	(0.1)	0	(0.0)	34	(0.5)
New York									
New York City	84,332	441	(0.5)	328	(0.4)	33	(0.0)	802	(1.0)
New York (excludes New York City)	26,553	237	(0.9)	129	(0.5)	16	(0.1)	382	(1.4)
North Carolina <sup>f</sup>	169,769	310	(0.2)	361	(0.2)	114	(0.1)	785	(0.5)
North Dakota <sup>f</sup>	4,958	11	(0.2)	3	(0.1)	0	(0.0)	14	(0.3)
Ohio	51,887	269	(0.5)	97	(0.2)	14	(0.0)	380	(0.7)
Oklahoma	10,680	47	(0.4)	42	(0.4)	1	(0.0)	90	(0.8)
Oregon	7,197	36	(0.5)	20	(0.3)	0	(0.0)	56	(0.8)
Pennsylvania									
Pennsylvania (excludes Philadelphia)	60,196	122	(0.2)	300	(0.5)	2	(0.0)	424	(0.7)
Philadelphia	51,463	181	(0.4)	284	(0.6)	6	(0.0)	471	(0.9)
Rhode Island <sup>f</sup>	3,089	6	(0.2)	2	(0.1)	3	(0.1)	11	(0.4)
South Carolina <sup>f</sup>	62,180	265	(0.4)	156	(0.3)	47	(0.1)	468	(0.8)
South Dakota <sup>f</sup>	1,764	3	(0.2)	0	(0.0)	1	(0.1)	4	(0.2)
Tennessee <sup>f</sup>	116,042	444	(0.4)	606	(0.5)	1	(0.0)	1,051	(0.9)
Texas									
Houston	107,133	300	(0.3)	875	(0.8)	0	(0.0)	1,175	(1.1)
Texas <sup>f</sup> (excludes Houston)	274,551	738	(0.3)	1,353	(0.5)	139	(0.1)	2,230	(0.8)
Utah <sup>f</sup>	2,568	15	(0.6)	5	(0.2)	0	(0.0)	20	(0.8)
Vermont	424	3	(0.7)	0	(0.0)	0	(0.0)	3	(0.7)
Virginia <sup>f</sup>	63,074	218	(0.3)	82	(0.1)	2	(0.0)	302	(0.5)
Washington <sup>f</sup>	14,190	63	(0.4)	31	(0.2)	6	(0.0)	100	(0.7)
West Virginia	5,106	9	(0.2)	5	(0.1)	1	(0.0)	15	(0.3)
Wisconsin	14,957	46	(0.3)	31	(0.2)	1	(0.0)	78	(0.5)
Wyoming	3,977	4	(0.1)	1	(0.0)	0	(0.0)	5	(0.1)
Puerto Rico	16,205	137	(0.8)	66	(0.4)	0	(0.0)	203	(1.3)
U.S. Virgin Islands <sup>f</sup>	1,516	16	(1.1)	8	(0.5)	1	(0.1)	25	(1.6)
<b>Total</b>	<b>2,758,212</b>	<b>10,622</b>	<b>(0.4)</b>	<b>12,289</b>	<b>(0.4)</b>	<b>949</b>	<b>(0.0)</b>	<b>23,860</b>	<b>(0.9)</b>

Data Source: 2018 NHM&E HIV test-level data reported through EvaluationWeb® as of September 16, 2019.

<sup>a</sup> Includes only tests with negative or positive results; tests with discordant or indeterminate results are excluded.

<sup>b</sup> Includes unconfirmed preliminary positive rapid tests and confirmed positive tests.

<sup>c</sup> A newly diagnosed HIV-positive test refers to a person who has a current HIV-positive test result (includes unconfirmed preliminary positive rapid tests and confirmed positive tests) and no indication of a previous HIV-positive test.

<sup>d</sup> A previously diagnosed HIV-positive test is a test on a client who was previously reported to the HIV surveillance system or who reports a previous positive HIV test or evidence of a previous positive test is found on review of other data sources.

<sup>e</sup> A positive test that was missing information on prior HIV status or was reported as unable to determine prior HIV status (i.e. the HIV surveillance system was not checked, no other data sources were reviewed and there is no information from the client about previous HIV test results).

<sup>f</sup> Recipients reported PS18-1802 data under both the old and the new NHM&E reporting requirements. Data were analyzed separately and resulting counts aggregated.



**Table 2. Number of CDC-funded HIV tests and newly diagnosed HIV positivity in health care and non-health care settings, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2018**

	Health care settings				Non-health care settings			
	HIV tests <sup>a</sup>		Newly diagnosed HIV-positive tests <sup>b</sup>		HIV tests <sup>a</sup>		Newly diagnosed HIV-positive tests <sup>b</sup>	
<b>CDC-funded jurisdiction</b>	<b>No.</b>	<b>(%)</b>	<b>No.</b>	<b>(%)</b>	<b>No.</b>	<b>(%)</b>	<b>No.</b>	<b>(%)</b>
Alabama	37,850	(42.7)	85	(0.2)	50,778	(57.3)	44	(0.1)
Alaska	289	(16.1)	1	(0.3)	1,443	(80.3)	1	(0.1)
Arizona	27,801	(71.8)	193	(0.7)	10,912	(28.2)	64	(0.6)
Arkansas	34,643	(91.9)	93	(0.3)	3,066	(8.1)	43	(1.4)
California								
Los Angeles	35,078	(34.5)	241	(0.7)	38,838	(38.2)	270	(0.7)
San Francisco	29,689	(88.4)	94	(0.3)	3,878	(11.6)	17	(0.4)
California (excludes Los Angeles and San Francisco)	35,002	(64.1)	157	(0.4)	12,351	(22.6)	102	(0.8)
Colorado	228	(10.8)	1	(0.4)	1,882	(88.9)	14	(0.7)
Connecticut <sup>c</sup>	58,850	(94.7)	92	(0.2)	3,272	(5.3)	20	(0.6)
Delaware <sup>c</sup>	6,420	(60.8)	9	(0.1)	4,145	(39.2)	7	(0.2)
District of Columbia <sup>c</sup>	6,247	(32.0)	13	(0.2)	13,259	(67.9)	65	(0.5)
Florida	184,529	(54.0)	823	(0.4)	153,292	(44.8)	797	(0.5)
Georgia <sup>c</sup>	84,324	(61.9)	379	(0.4)	51,875	(38.1)	662	(1.3)
Hawaii	1,151	(36.8)	8	(0.7)	1,980	(63.2)	11	(0.6)
Idaho <sup>c</sup>	1,685	(41.1)	1	(0.1)	2,418	(58.9)	4	(0.2)
Illinois								
Chicago	55,477	(83.8)	24	(0.0)	10,728	(16.2)	93	(0.9)
Illinois (excludes Chicago)	17,624	(61.2)	14	(0.1)	11,154	(38.8)	34	(0.3)
Indiana <sup>c</sup>	12,102	(60.7)	44	(0.4)	7,842	(39.3)	33	(0.4)
Iowa	8,810	(82.7)	23	(0.3)	1,847	(17.3)	3	(0.2)
Kansas	14,293	(84.3)	27	(0.2)	2,658	(15.7)	35	(1.3)
Kentucky <sup>c</sup>	15,228	(74.4)	56	(0.4)	5,246	(25.6)	19	(0.4)
Louisiana	94,165	(84.1)	330	(0.4)	17,738	(15.8)	128	(0.7)
Maine	947	(58.8)	4	(0.4)	663	(41.2)	0	(0.0)
Maryland								
Baltimore <sup>c</sup>	36,553	(80.6)	113	(0.3)	8,797	(19.4)	30	(0.3)
Maryland <sup>c</sup> (excludes Baltimore)	30,423	(86.0)	89	(0.3)	4,875	(13.8)	9	(0.2)
Massachusetts <sup>c</sup>	36,027	(90.7)	147	(0.4)	3,708	(9.3)	12	(0.3)
Michigan <sup>c</sup>	47,764	(91.0)	109	(0.2)	4,720	(9.0)	28	(0.6)
Minnesota <sup>c</sup>	2,110	(42.5)	5	(0.2)	2,853	(57.5)	8	(0.3)
Mississippi <sup>c</sup>	38,600	(71.2)	118	(0.3)	15,582	(28.8)	6	(0.0)
Missouri	78,131	(85.7)	145	(0.2)	13,048	(14.3)	80	(0.6)
Montana <sup>c</sup>	871	(42.0)	0	(0.0)	1,204	(58.0)	1	(0.1)
Nebraska <sup>c</sup>	6,227	(72.0)	14	(0.2)	2,417	(28.0)	5	(0.2)
Nevada	9,295	(43.8)	68	(0.7)	11,910	(56.2)	103	(0.9)
New Hampshire <sup>c</sup>	391	(43.7)	7	(1.8)	504	(56.3)	0	(0.0)

	Health care settings				Non-health care settings			
	HIV tests <sup>a</sup>		Newly diagnosed HIV-positive tests <sup>b</sup>		HIV tests <sup>a</sup>		Newly diagnosed HIV-positive tests <sup>b</sup>	
	No.	(%)	No.	(%)	No.	(%)	No.	(%)
<b>CDC-funded jurisdiction</b>	<b>No.</b>	<b>(%)</b>	<b>No.</b>	<b>(%)</b>	<b>No.</b>	<b>(%)</b>	<b>No.</b>	<b>(%)</b>
New Jersey <sup>c</sup>	16,811	(60.1)	100	(0.6)	11,182	(39.9)	81	(0.7)
New Mexico	6,776	(90.2)	19	(0.3)	733	(9.8)	5	(0.7)
New York								
New York City	74,884	(88.8)	326	(0.4)	8,712	(10.3)	111	(1.3)
New York (excludes New York City)	5,614	(21.1)	121	(2.2)	20,939	(78.9)	116	(0.6)
North Carolina <sup>c</sup>	136,281	(80.3)	214	(0.2)	33,113	(19.5)	95	(0.3)
North Dakota <sup>c</sup>	110	(2.2)	0	(0.0)	4,848	(97.8)	11	(0.2)
Ohio	37,933	(73.1)	205	(0.5)	13,698	(26.4)	62	(0.5)
Oklahoma	8,184	(76.6)	15	(0.2)	2,477	(23.2)	32	(1.3)
Oregon	4,806	(66.8)	26	(0.5)	2,336	(32.5)	10	(0.4)
Pennsylvania								
Pennsylvania (excludes Philadelphia)	52,893	(87.9)	84	(0.2)	7,303	(12.1)	38	(0.5)
Philadelphia	40,048	(77.8)	125	(0.3)	11,415	(22.2)	56	(0.5)
Rhode Island <sup>c</sup>	0	(0.0)	0	(0.0)	3,089	(100.0)	6	(0.2)
South Carolina <sup>c</sup>	50,248	(80.8)	144	(0.3)	11,773	(18.9)	120	(1.0)
South Dakota <sup>c</sup>	1,383	(78.4)	1	(0.1)	381	(21.6)	2	(0.5)
Tennessee <sup>c</sup>	107,181	(92.4)	335	(0.3)	8,861	(7.6)	109	(1.2)
Texas								
Houston	99,230	(92.6)	213	(0.2)	7,896	(7.4)	87	(1.1)
Texas <sup>c</sup> (excludes Houston)	228,318	(83.2)	444	(0.2)	44,531	(16.2)	287	(0.6)
Utah <sup>c</sup>	2,426	(94.5)	13	(0.5)	142	(5.5)	2	(1.4)
Vermont	36	(8.5)	0	(0.0)	388	(91.5)	3	(0.8)
Virginia <sup>c</sup>	49,523	(78.5)	134	(0.3)	13,523	(21.4)	84	(0.6)
Washington <sup>c</sup>	6,164	(43.4)	35	(0.6)	8,026	(56.6)	28	(0.3)
West Virginia	3,881	(76.0)	3	(0.1)	1,225	(24.0)	6	(0.5)
Wisconsin	5,726	(38.3)	14	(0.2)	9,231	(61.7)	32	(0.3)
Wyoming	3,934	(98.9)	4	(0.1)	43	(1.1)	0	(0.0)
Puerto Rico	10,046	(62.0)	109	(1.1)	6,159	(38.0)	28	(0.5)
U.S. Virgin Islands <sup>c</sup>	959	(63.3)	16	(1.7)	557	(36.7)	0	(0.0)
<b>Total</b>	<b>2,002,219</b>	<b>(72.6)</b>	<b>6,227</b>	<b>(0.3)</b>	<b>713,464</b>	<b>(25.9)</b>	<b>4,159</b>	<b>(0.6)</b>

Data Source: 2018 NHM&E HIV test-level data reported through EvaluationWeb® as of September 16, 2019.

<sup>a</sup> Includes only tests with negative or positive results; tests with discordant or indeterminate results are excluded.

<sup>b</sup> A newly diagnosed HIV-positive test refers to a person who has a current HIV-positive test result (includes unconfirmed preliminary positive rapid tests and confirmed positive tests) and no indication of a previous HIV-positive test.

<sup>c</sup> Recipients reported PS18-1802 data under both the old and the new NHM&E reporting requirements. Data were analyzed separately and resulting counts aggregated.

**Table 3. CDC-funded HIV testing and linkage to HIV medical care among persons newly diagnosed with HIV, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2018**

CDC funded jurisdiction	HIV tests			Linkage to HIV Medical Care in 90 days <sup>c</sup>					
	All HIV tests <sup>a</sup>	Newly diagnosed HIV-positive tests <sup>b</sup>	Newly diagnosed HIV positivity (%)	Linked	Not linked	Missing /invalid	Missing /invalid (%)	Denominator for reported percentage <sup>d</sup>	Reported percentage <sup>e</sup> (%)
Alabama	88,628	129	(0.1)	16	17	96	(74.4)	33	(48.5)
Alaska	1,796	2	(0.1)	2	0	0	(0.0)	2	(100.0)
Arizona	38,713	257	(0.7)	166	43	48	(18.7)	209	(79.4)
Arkansas	37,709	136	(0.4)	28	88	20	(14.7)	116	(24.1)
California									
Los Angeles	101,591	666	(0.7)	470	80	116	(17.4)	550	(85.5)
San Francisco	33,567	111	(0.3)	99	11	1	(0.9)	110	(90.0)
California (excludes Los Angeles and San Francisco)	54,595	308	(0.6)	216	61	31	(10.1)	277	(78.0)
Colorado	2,118	16	(0.8)	9	3	4	(25.0)	12	(75.0)
Connecticut <sup>f</sup>	62,122	112	(0.2)	94	9	9	(8.0)	103	(91.3)
Delaware <sup>f</sup>	10,565	16	(0.2)	7	3	6	(37.5)	10	(70.0)
District of Columbia <sup>f</sup>	19,524	78	(0.4)	53	1	24	(30.8)	54	(98.1)
Florida	341,836	1,635	(0.5)	1,471	35	129	(7.9)	1,506	(97.7)
Georgia <sup>f</sup>	136,201	1,041	(0.8)	757	177	107	(10.3)	934	(81.0)
Hawaii	3,131	19	(0.6)	10	4	5	(26.3)	14	(71.4)
Idaho <sup>f</sup>	4,103	5	(0.1)	5	0	0	(0.0)	5	(100.0)
Illinois									
Chicago	66,205	117	(0.2)	50	33	34	(29.1)	83	(60.2)
Illinois (excludes Chicago)	28,778	48	(0.2)	33	11	4	(8.3)	44	(75.0)
Indiana <sup>f</sup>	19,944	77	(0.4)	21	5	51	(66.2)	26	(80.8)
Iowa	10,657	26	(0.2)	26	0	0	(0.0)	26	(100.0)
Kansas	16,951	62	(0.4)	56	4	2	(3.2)	60	(93.3)
Kentucky <sup>f</sup>	20,474	75	(0.4)	20	1	54	(72.0)	21	(95.2)
Louisiana	111,978	458	(0.4)	373	79	6	(1.3)	452	(82.5)
Maine	1,610	4	(0.2)	3	1	0	(0.0)	4	(75.0)
Maryland									
Baltimore <sup>f</sup>	45,350	143	(0.3)	92	38	13	(9.1)	130	(70.8)
Maryland (excludes Baltimore)	35,391	99	(0.3)	59	22	18	(18.2)	81	(72.8)
Massachusetts <sup>f</sup>	39,735	159	(0.4)	142	9	8	(5.0)	151	(94.0)
Michigan <sup>f</sup>	52,484	137	(0.3)	113	6	18	(13.1)	119	(95.0)
Minnesota <sup>f</sup>	4,963	13	(0.3)	5	0	8	(61.5)	5	(100.0)
Mississippi <sup>f</sup>	54,182	124	(0.2)	42	6	76	(61.3)	48	(87.5)
Missouri	91,179	225	(0.2)	169	23	33	(14.7)	192	(88.0)
Montana <sup>f</sup>	2,075	1	(0.0)	1	0	0	(0.0)	1	(100.0)
Nebraska <sup>f</sup>	8,644	19	(0.2)	2	2	15	(78.9)	4	(50.0)
Nevada	21,205	171	(0.8)	136	18	17	(9.9)	154	(88.3)
New Hampshire <sup>f</sup>	895	7	(0.8)	7	0	0	(0.0)	7	(100.0)

CDC funded jurisdiction	HIV tests			Linkage to HIV Medical Care in 90 days <sup>c</sup>					
	All HIV tests <sup>a</sup>	Newly diagnosed HIV-positive tests <sup>b</sup>	Newly diagnosed HIV positivity (%)	Linked	Not linked	Missing /invalid	Missing /invalid (%)	Denominator for reported percentage <sup>d</sup>	Reported percentage <sup>e</sup> (%)
New Jersey <sup>f</sup>	27,993	181	(0.6)	147	31	3	(1.7)	178	(82.6)
New Mexico	7,509	24	(0.3)	22	2	0	(0.0)	24	(91.7)
New York									
New York City	84,332	441	(0.5)	255	50	136	(30.8)	305	(83.6)
New York (excludes New York City)	26,553	237	(0.9)	193	3	41	(17.3)	196	(98.5)
North Carolina <sup>f</sup>	169,769	310	(0.2)	243	15	52	(16.8)	258	(94.2)
North Dakota <sup>f</sup>	4,958	11	(0.2)	9	1	1	(9.1)	10	(90.0)
Ohio	51,887	269	(0.5)	198	16	55	(20.4)	214	(92.5)
Oklahoma	10,680	47	(0.4)	22	3	22	(46.8)	25	(88.0)
Oregon	7,197	36	(0.5)	30	5	1	(2.8)	35	(85.7)
Pennsylvania									
Pennsylvania (excludes Philadelphia)	60,196	122	(0.2)	97	9	16	(13.1)	106	(91.5)
Philadelphia	51,463	181	(0.4)	138	17	26	(14.4)	155	(89.0)
Rhode Island <sup>f</sup>	3,089	6	(0.2)	4	0	2	(33.3)	4	(100.0)
South Carolina <sup>f</sup>	62,180	265	(0.4)	234	12	19	(7.2)	246	(95.1)
South Dakota <sup>f</sup>	1,764	3	(0.2)	0	0	3	(100.0)	0	(0.0)
Tennessee <sup>f</sup>	116,042	444	(0.4)	253	53	138	(31.1)	306	(82.7)
Texas									
Houston	107,133	300	(0.3)	187	8	105	(35.0)	195	(95.9)
Texas <sup>f</sup> (excludes Houston)	274,551	738	(0.3)	439	188	111	(15.0)	627	(70.0)
Utah <sup>f</sup>	2,568	15	(0.6)	8	1	6	(40.0)	9	(88.9)
Vermont	424	3	(0.7)	3	0	0	(0.0)	3	(100.0)
Virginia <sup>f</sup>	63,074	218	(0.3)	155	15	48	(22.0)	170	(91.2)
Washington <sup>f</sup>	14,190	63	(0.4)	54	3	6	(9.5)	57	(94.7)
West Virginia	5,106	9	(0.2)	3	0	6	(66.7)	3	(100.0)
Wisconsin	14,957	46	(0.3)	44	0	2	(4.3)	44	(100.0)
Wyoming	3,977	4	(0.1)	1	0	3	(75.0)	1	(100.0)
Puerto Rico	16,205	137	(0.8)	130	4	3	(2.2)	134	(97.0)
U.S. Virgin Islands <sup>f</sup>	1,516	16	(1.1)	13	2	1	(6.3)	15	(86.7)
<b>Total</b>	<b>2,758,212</b>	<b>10,622</b>	<b>(0.4)</b>	<b>7,635</b>	<b>1,228</b>	<b>1,759</b>	<b>(16.6)</b>	<b>8,863</b>	<b>(86.1)</b>

Data Source: 2018 NHM&E HIV test-level data reported through EvaluationWeb<sup>®</sup> as of September 16, 2019.

<sup>a</sup> Includes only tests with negative or positive results; tests with discordant or indeterminate results are excluded.

<sup>b</sup> A newly diagnosed HIV-positive test refers to a person who has a current HIV-positive test result (includes unconfirmed preliminary positive rapid tests and confirmed positive tests) and no indication of a previous HIV-positive test.

<sup>c</sup> A person is considered linked to HIV medical care within 90 days if they have attended an appointment for HIV medical care within 90 days of diagnosis.

<sup>d</sup> Number of persons with newly diagnosed HIV whose test records have valid and complete information on attendance and date of first appointment for HIV medical care within 90 days. This is the denominator used to calculate the reported percentage.

<sup>e</sup> This is the value used to determine whether a health department has met their funding opportunity target.

<sup>f</sup> Recipients reported PS18-1802 data under both the old and the new NHM&E reporting requirements. Data were analyzed separately and resulting counts aggregated.

**Table 4. CDC-funded HIV testing and linkage to HIV medical care among persons newly diagnosed with HIV by demographic characteristics, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2018**

Characteristics	HIV tests				Linkage to HIV medical care in 90 days <sup>d</sup>					
	All tests <sup>a</sup>	Percent of all tests <sup>b</sup> (%)	Newly diagnosed HIV-positive tests <sup>c</sup>	Newly diagnosed HIV positivity (%)	Linked	Not linked	Missing /Invalid	Missing /Invalid (%)	Denominator for report percentage <sup>e</sup>	Reported percentage <sup>f</sup> (%)
<b>Age at test (years)</b>										
<13	3,537	(0.1)	12	(0.3)	7	3	2	(16.7)	10	(70.0)
13-19	185,809	(6.7)	399	(0.2)	259	48	92	(23.1)	307	(84.4)
20-29	1,024,508	(37.1)	4,644	(0.5)	3,373	479	792	(17.1)	3,852	(87.6)
30-39	685,476	(24.9)	3,018	(0.4)	2,163	369	486	(16.1)	2,532	(85.4)
40-49	375,746	(13.6)	1,324	(0.4)	963	162	199	(15.0)	1,125	(85.6)
50+	449,357	(16.3)	1,213	(0.3)	862	166	185	(15.3)	1,028	(83.9)
Missing/invalid	33,779	(1.2)	12	(0.0)	8	1	3	(25.0)	9	(88.9)
<b>Gender</b>										
Male	1,408,907	(51.1)	8,750	(0.6)	6,398	953	1,399	(16.0)	7,351	(87.0)
Female	1,316,501	(47.7)	1,602	(0.1)	1,056	238	308	(19.2)	1,294	(81.6)
Transgender	17,721	(0.6)	239	(1.3)	159	35	45	(18.8)	194	(82.0)
Declined/Not asked/ Other	13,807	(0.5)	12	(0.1)	8	2	2	(16.7)	10	(80.0)
Missing/invalid	1,276	(0.0)	19	(1.5)	14	0	5	(26.3)	14	(100.0)
<b>Race/Ethnicity</b>										
White	712,689	(25.8)	2,002	(0.3)	1,435	204	363	(18.1)	1,639	(87.6)
Black or African American	1,084,456	(39.3)	4,999	(0.5)	3,489	630	880	(17.6)	4,119	(84.7)
Hispanic or Latino	604,946	(21.9)	2,744	(0.5)	2,138	241	365	(13.3)	2,379	(89.9)
Asian	61,068	(2.2)	190	(0.3)	136	14	40	(21.1)	150	(90.7)
American Indian or Alaska Native	14,482	(0.5)	45	(0.3)	33	4	8	(17.8)	37	(89.2)
Native Hawaiian or Pacific Islander	5,318	(0.2)	26	(0.5)	19	3	4	(15.4)	22	(86.4)
Multi-race	26,098	(0.9)	120	(0.5)	93	7	20	(16.7)	100	(93.0)
Declined	25,719	(0.9)	55	(0.2)	36	5	14	(25.5)	41	(87.8)
Don't know/not asked	136,359	(4.9)	214	(0.2)	88	96	30	(14.0)	184	(47.8)
Missing/invalid	87,077	(3.2)	227	(0.3)	168	24	35	(15.4)	192	(87.5)
<b>Subpopulation in non-health care facilities<sup>g</sup></b>										
Men who have sex with men and who inject drugs	5,212	(0.7)	121	(2.3)	87	15	19	(15.7)	102	(85.3)
Men who have sex with men	163,699	(22.9)	2,694	(1.6)	2,099	226	369	(13.7)	2,325	(90.3)
Transgender who inject drugs	545	(0.1)	12	(2.2)	6	3	3	(25.0)	9	(66.7)
Transgender	8,729	(1.2)	109	(1.2)	75	18	16	(14.7)	93	(80.6)
Persons who inject drugs	37,387	(5.2)	128	(0.3)	81	15	32	(25.0)	96	(84.4)
Heterosexual men	169,163	(23.7)	429	(0.3)	295	57	77	(17.9)	352	(83.8)
Heterosexual women	206,523	(28.9)	367	(0.2)	228	60	79	(21.5)	288	(79.2)
Women who have sex with women	8,868	(1.2)	4	(0.0)	1	0	3	(75.0)	1	(100.0)

Characteristics	HIV tests				Linkage to HIV medical care in 90 days <sup>d</sup>					
	All tests <sup>a</sup>	Percent of all tests <sup>b</sup> (%)	Newly diagnosed HIV-positive tests <sup>c</sup>	Newly diagnosed HIV positivity (%)	Linked	Not linked	Missing /Invalid	Missing /Invalid (%)	Denominator for report percentage <sup>e</sup>	Reported percentage <sup>f</sup> (%)
Sex with transgender	604	(0.1)	3	(0.5)	3	0	0	(0.0)	3	(100.0)
No sexual contact or IDU, past 12 months	47,358	(6.6)	152	(0.3)	88	22	42	(27.6)	110	(80.0)
Missing/invalid	65,376	(9.2)	140	(0.2)	95	18	27	(19.3)	113	(84.1)
<b>Region</b>										
Northeast	358,412	(13.0)	1,453	(0.4)	1,083	129	241	(16.6)	1,212	(89.4)
Midwest	373,371	(13.5)	1,053	(0.3)	726	101	226	(21.5)	827	(87.8)
South	1,710,373	(62.0)	6,265	(0.4)	4,454	761	1,050	(16.8)	5,215	(85.4)
West	298,335	(10.8)	1,698	(0.6)	1,229	231	238	(14.0)	1,460	(84.2)
U.S. dependent areas	17,721	(0.6)	153	(0.9)	143	6	4	(2.6)	149	(96.0)
<b>Testing site type</b>										
Health care facilities	2,002,219	(72.6)	6,227	(0.3)	4,442	735	1,050	(16.9)	5,177	(85.8)
Non-health care facilities	713,464	(25.9)	4,159	(0.6)	3,058	434	667	(16.0)	3,492	(87.6)
Mobile units	518	(0.0)	0	(0.0)	0	0	0	(0.0)	0	(0.0)
Unknown	42,011	(1.5)	236	(0.6)	135	59	42	(17.8)	194	(69.6)
<b>Total</b>	<b>2,758,212</b>	<b>(100.0)</b>	<b>10,622</b>	<b>(0.4)</b>	<b>7,635</b>	<b>1,228</b>	<b>1,759</b>	<b>(16.6)</b>	<b>8,863</b>	<b>(86.1)</b>

Data Source: 2018 NHM&E HIV test-level data reported through EvaluationWeb® as of September 16, 2019.

<sup>a</sup> Includes only tests with negative or positive results; tests with discordant or indeterminate results are excluded.

<sup>b</sup> Sums may not total 100.0% due to rounding.

<sup>c</sup> A newly diagnosed HIV-positive test refers to a person who has a current HIV-positive test result (includes unconfirmed preliminary positive rapid tests and confirmed positive tests) and no indication of a previous HIV-positive test.

<sup>d</sup> A person is considered linked to HIV medical care within 90 days if they have attended an appointment for HIV medical care within 90 days of diagnosis.

<sup>e</sup> Number of persons with newly diagnosed HIV whose test records have valid and complete information on attendance and date of first appointment for HIV medical care within 90 days. This is the denominator used to calculate the reported percentage.

<sup>f</sup> This is the value used to determine whether a health department has met their funding opportunity target.

<sup>g</sup> Restricted to non-health care settings because data on subpopulation are required in non-health care settings, but only required for HIV-positive tests in health care settings.